Abstract:Objective This study endeavored to explore the optimal treatment strategy and conduct a prognostic analysis for patients diagnosed with pT4M0 (pathologic stage T4) colon adenocarcinoma (COAD). Methods and materials A total of 8,843 patients diagnosed with pT4M0 COAD between January 2010 and December 2015 were included in this study from the Surveillance, Epidemiology, and End Results (SEER) database. These patients were randomly divided into a training set and an internal validation set using a 7:3 ratio. Variables that demonstrated statistical significance (P<0.05) in univariate COX regression analysis or held clinical significance were incorporated into the multivariate COX regression model. Subsequently, this model was utilized to formulate a nomogram. The predictive accuracy and discriminability of the nomogram were assessed using the C-index, area under the curve (AUC), and calibration curves. Decision curve analysis (DCA) was conducted to confirm the clinical validity of the model. Results In the entire SEER cohort, the 3-year overall survival (OS) rate (74.22% vs. 63.20%, P<0.001) and the 3-year cancer-specific survival (CSS) rate (76.25% vs. 66.98%, P<0.001) in the surgery combined with postoperative adjuvant therapy (S+ADT) group surpassed those in the surgery (S) group. Multivariate COX regression analysis of the training set unveiled correlations between age, race, N stage, serum CEA (carcinoembryonic antigen), differentiation, number of resected lymph nodes, and treatment modalities with OS and CSS. Nomograms for OS and CSS were meticulously crafted based on these variables, achieving C-indexes of 0.692 and 0.690 in the training set, respectively. The robust predictive ability of the nomogram was further affirmed through receiver operating characteristic (ROC) and calibration curves in both the training and validation sets. Conclusion In individuals diagnosed with pT4M0 COAD, the integration of surgery with adjuvant chemoradiotherapy demonstrated a substantial extension of long-term survival. The nomogram, which incorporated key factors such as age, race, differentiation, N stage, serum CEA level, tumor size, and the number of resected lymph nodes, stood as a dependable tool for predicting OS and CSS rates. This predictive model held promise in aiding clinicians by identifying high-risk patients and facilitating the development of personalized treatment plans.

P-TNM Staging System for Colon Cancer: Combination of P-stage and AJCC TNM Staging System for Improving Prognostic Prediction and Clinical Management

Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer

Combination of Carcinoembryonic Antigen with the American Joint Committee on Cancer TNM Staging System in Rectal Cancer: a Real-World and Large Population-Based Study

Exploration of a modified stage for pN0 colon cancer patients

Implications of Pretreatment Serum Carcinoembryonic Antigen Levels and Perineural Invasion with Staging, Prognosis, and Management in Stage I-III Colon Cancer after Surgery: A Retrospective Cohort Study in the SEER Database

Associations Of P Score With Real-World Survival Improvement Offered By Adjuvant Chemotherapy In Stage Ii Colon Cancer: A Large Population-Based Longitudinal Cohort Study

Real-World Implications of Nonbiological Factors with Staging, Prognosis and Clinical Management in Colon Cancer

A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer

Modification Of N Staging Systems For Penile Cancer: A More Precise Prediction Of Prognosis (Vol 112, Pg 1766, 2015)

Prognostic and Survival Analysis of 837 Chinese Colorectal Cancer Patients.

Improving the Prognosis of Colon Cancer Through Knowledge-Based Clinical-Molecular Integrated Analysis

Prognostic Validation and Therapeutic Decision-Making of the AJCC Eighth Pathological Prognostic Staging for T3N0 Breast Cancer after Mastectomy

Verification of T-Plus Staging System for Colorectal Cancer Based on Nomogram Analysis of Single Center'S 25-Year Follow-Up.

A Modified Tumor-Node-Metastasis Staging System for Colon Cancer Patients with Fewer than Twelve Lymph Nodes Examined

Real‐world Implications of Nonbiological Factors with Staging, Clinical Management, and Prognostic Prediction in Pancreatic Ductal Adenocarcinoma

Evaluation of the 8th Edition of the American Joint Committee on Cancer's Pathological Staging System in Prognosis Assessment and Treatment Decision Making for Stage T1-2N1 Breast Cancer after Mastectomy.

Optimal treatment strategy and prognostic analysis for patients with non-metastatic pT4 colon adenocarcinoma

Combination of DNA Ploidy, Stroma, and Nucleotyping Predicting Prognosis and Tailoring Adjuvant Chemotherapy Duration in Stage III Colon Cancer

Prognostic Effects of Clinical and Pathologic Tnm Stages in Patients with Locally Advanced Rectum Carcinoma after Neoadjuvant Chemoradiotherapy

Prognostic and Predictive Value of the American Joint Committee on Cancer Pathological Prognostic Staging System in Nodal Micrometastatic Breast Cancer

Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study.